If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
577.50    5.50 (0.96%)
Bid:
577.00
Ask:
577.50
Spread: 0.50 (0.087%)
Market Cap: £1.56b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
 



 FOR IMMEDIATE RELEASE 24 JUNE 2014

 

CHEMRING GROUP PLC

 

Directorate change

 

Michael Flowers appointed Group Chief Executive

 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect. Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

 

Michael Flowers has spent 13 years in senior management positions within the defence industry. He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science. After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

 

Mark Papworth has stepped down from the Board of Chemring with immediate effect. 

 

Peter Hickson, Chairman of Chemring, said:

 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost base and we are grateful for his leadership during this period.

 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created. To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

 

Ends

 

 

 

 

For further information, contact:

 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDLSBDBGSX
Date   Source Headline
22nd Jan 201810:00 amRNSDirector/PDMR Shareholding
18th Jan 20187:00 amRNSFULL YEAR RESULTS
3rd Jan 20189:59 amRNSBlock listing Interim Review
2nd Jan 20189:55 amRNSTotal Voting Rights
19th Dec 201710:30 amRNSHolding(s) in Company
19th Dec 201710:21 amRNSHolding(s) in Company
14th Dec 20175:09 pmRNSHolding(s) in Company
11th Dec 201711:26 amRNSHolding(s) in Company
1st Dec 20179:43 amRNSTotal Voting Rights
27th Nov 201711:05 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSPOST-CLOSE STATEMENT
1st Nov 20179:05 amRNSTotal Voting Rights
30th Oct 20174:02 pmRNSHolding(s) in Company
27th Oct 20171:03 pmRNSHolding(s) in Company
27th Oct 201710:10 amRNSDirector Declaration
6th Oct 20177:00 amRNSContract Update
2nd Oct 20179:44 amRNSTotal Voting Rights
20th Sep 20174:39 pmRNSHolding(s) in Company
18th Sep 20175:09 pmRNSHolding(s) in Company
5th Sep 20177:00 amRNSTrading Update
1st Sep 20179:47 amRNSTotal Voting Rights
7th Aug 20177:00 amRNSContract Award
1st Aug 20179:37 amRNSTotal Voting Rights
31st Jul 20177:00 amRNSCONTRACT AWARD
27th Jul 20171:09 pmRNSDirector/PDMR Shareholding
27th Jul 20171:08 pmRNSDirector/PDMR Shareholding
27th Jul 201711:15 amRNSHolding(s) in Company
4th Jul 201710:32 amRNSHolding(s) in Company
3rd Jul 20179:54 amRNSTotal Voting Rights
23rd Jun 201710:25 amRNSDirector/PDMR Shareholding
22nd Jun 20177:00 amRNSHalf-year Report
20th Jun 20172:10 pmRNSBlock listing Interim Review
20th Jun 20179:15 amRNSBlock listing Interim Review
1st Jun 201710:55 amRNSTotal Voting Rights
31st May 20173:13 pmRNSHolding(s) in Company
2nd May 20172:37 pmRNSTotal Voting Rights
3rd Apr 20179:30 amRNSTotal Voting Rights
31st Mar 201711:47 amRNSHolding(s) in Company
24th Mar 20171:54 pmRNSDirector/PDMR Shareholding
24th Mar 20171:53 pmRNSDirector/PDMR Shareholding
24th Mar 20171:51 pmRNSDirector/PDMR Shareholding
20th Mar 20177:00 amRNSResults of AGM
17th Mar 20177:00 amRNSAGM Statement
17th Mar 20177:00 amRNSWithdrawal of AGM resolutions
1st Mar 20173:03 pmRNSTotal Voting Rights
1st Mar 20172:11 pmRNSHolding(s) in Company
28th Feb 20179:27 amRNSHolding(s) in Company
22nd Feb 201711:38 amRNSAdditional Listing
21st Feb 20171:50 pmRNSBlock listing Interim Review
15th Feb 20179:48 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.